Oncoclinicas stock: Debt talks cover BRL 5.1 billion. Oncoclinicas stock faces a tender offer

Published on 10/23/2026 at 01:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Debt talks cover BRL 5.1 billion, with a tender offer due October 26, 2026. Oncoclinicas stock faces a board vote after a resignation.

Restructuring and governance

On October 16, 2026, debt talks covered BRL 5.1 billion alongside a tender offer.
Valor International reported support from 70 percent of creditors.
Oncoclinicas stock was last at BRL 1.00 on October 22, 2026 at 5:05 p.m. BRT on B3.

Oncoclinicas, BRONCOACNOR6, Illustration mit AI erstellt.

Oncoclinicas (BRONCOACNOR6) is negotiating BRL 5.1 billion of debt while a tender offer for its shares is scheduled for October 26, 2026, according to Valor International on October 16, 2026. The restructuring process and a proposed board overhaul now define the investment case.

Debt restructuring sets the stakes

Valor International reported that the out-of-court restructuring covers BRL 5.1 billion and that the tender offer could reach BRL 14 billion. The offer is linked to a dispute involving Latache Capital, minority shareholders and the Josephina III fund of Centaurus.

The same report said the restructuring had support from 70 percent of creditors, while the plan included a 45 percent haircut for one creditor group. That combination puts the eventual debt terms and the tender offer deadline at the center of the stock story.

Three dates changed the story

On July 13, 2026, Oncoclinicas filed for an out-of-court restructuring covering BRL 5.1 billion, as UOL reported on October 13, 2026. On October 1, 2026, director Paulo Roberto Belém Junior resigned, according to The Globe and Mail. On October 16, 2026, Valor International detailed the debt talks and tender offer dispute.

What happens on October 26?

The October 26, 2026 tender offer date is the next explicit corporate deadline in the reported timeline. The legal contest could alter the timetable, while the company is also moving toward a new shareholder meeting after the board resignation.

Governance adds a second risk

The board dispute is material because the former director was elected through cumulative voting. Valor International reported that his resignation resulted in the removal of the entire board, leaving interim directors in place until the end of October. UOL also reported that Oncoclinicas completed 114,000 treatments in the second quarter of 2026, a 30 percent decline from the same period of 2025, adding an operating comparison to the balance-sheet pressure.

Brazil quote and company profile

Oncoclinicas operates oncology clinics and treatment centers across Brazil. Its website says the network has more than 140 units in 49 cities. The last available B3 quote stood at BRL 1.00 on October 22, 2026 at 5:05 p.m. BRT, giving investors a dated market reference while the restructuring timetable develops.